Company / SG&A Expense
ORTHOPEDIATRICS CORP SG&A Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$73.3M
FY2025
5-year range
$26.7M / $73.3M
FY2021-FY2025
Trend
+26.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 8 consecutive years, from $11M in FY2017 to $73M in FY2025.
Based on SEC 10-K filings.
$73M in FY2025 with a 5-year CAGR of +28.5%.
Increased from $46M to $73M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +24.1%
- 5-Year CAGR
- +28.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- ORTHOPEDIATRICS CORP's sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +28.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 26.6% year-over-year.
- Lowest sg&a expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.3M | +26.6% |
| FY2024 | $57.9M | +25.7% |
| FY2023 | $46.1M | +20.2% |
| FY2022 | $38.3M | +43.7% |
| FY2021 | $26.7M | +27.3% |
| FY2020 | $20.9M | +23.4% |
| FY2019 | $17.0M | +45.9% |
| FY2018 | $11.6M | +2.0% |
| FY2017 | $11.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026